Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
If approved, Inrebic will become the first new therapy for myelofibrosis in Europe in nearly a decade Inrebic, if approved, will also be the first once-daily, oral therapy to demonstrate clinically meaningful spleen and symptom response for patients with myelofibrosis where treatment with ruxolitinib has failed or who are JAK inhibitor naïve Bristol Myers Squibb today announced the Committee for Medicinal Products … If approved, Inrebic will become the first new therapy for myelofibrosis in Europe in nearly a decade Inrebic, if approved, will also be the first once-daily, oral therapy t...
Source: investingnews.com